JP2016511405A - 結合性タンパク質相互作用及び結合性分子の選択及び多様化のための細胞に基づく方法 - Google Patents

結合性タンパク質相互作用及び結合性分子の選択及び多様化のための細胞に基づく方法 Download PDF

Info

Publication number
JP2016511405A
JP2016511405A JP2015560136A JP2015560136A JP2016511405A JP 2016511405 A JP2016511405 A JP 2016511405A JP 2015560136 A JP2015560136 A JP 2015560136A JP 2015560136 A JP2015560136 A JP 2015560136A JP 2016511405 A JP2016511405 A JP 2016511405A
Authority
JP
Japan
Prior art keywords
antibody
receptor
protein
binding
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015560136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016511405A5 (enExample
Inventor
ゴンカルベス ジョアン マヌエル ブラス
ゴンカルベス ジョアン マヌエル ブラス
アイレス ダ シルバ フレデリコ ヌノ カスタニェイラ
アイレス ダ シルバ フレデリコ ヌノ カスタニェイラ
コルテ−レアル ソフィア フォルカー
コルテ−レアル ソフィア フォルカー
デ オリヴェイラ ソライア ラファエラ サンティアゴ
デ オリヴェイラ ソライア ラファエラ サンティアゴ
Original Assignee
テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー
テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー, テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー filed Critical テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー
Publication of JP2016511405A publication Critical patent/JP2016511405A/ja
Publication of JP2016511405A5 publication Critical patent/JP2016511405A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1024—In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015560136A 2013-03-01 2014-03-03 結合性タンパク質相互作用及び結合性分子の選択及び多様化のための細胞に基づく方法 Pending JP2016511405A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771562P 2013-03-01 2013-03-01
US61/771,562 2013-03-01
PCT/PT2014/000016 WO2014133405A2 (en) 2013-03-01 2014-03-03 Cell-based methods for coupling protein interactions and binding molecule selection and diversification

Publications (2)

Publication Number Publication Date
JP2016511405A true JP2016511405A (ja) 2016-04-14
JP2016511405A5 JP2016511405A5 (enExample) 2017-04-06

Family

ID=50680097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015560136A Pending JP2016511405A (ja) 2013-03-01 2014-03-03 結合性タンパク質相互作用及び結合性分子の選択及び多様化のための細胞に基づく方法

Country Status (6)

Country Link
US (1) US9487773B2 (enExample)
EP (2) EP3588089B1 (enExample)
JP (1) JP2016511405A (enExample)
ES (1) ES2872048T3 (enExample)
PT (1) PT3588089T (enExample)
WO (1) WO2014133405A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020510438A (ja) * 2017-03-15 2020-04-09 オックスフォード ジェネティクス リミテッドＯｘｆｏｒｄ Ｇｅｎｅｔｉｃｓ Ｌｉｍｉｔｅｄ 抗体の選択方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944647C (en) 2014-04-03 2025-07-08 Igm Biosciences Inc MODIFIED J STRING
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
IL297997A (en) 2015-03-04 2023-01-01 Igm Biosciences Inc Cd20 binding molecules and uses thereof
HUE069387T2 (hu) 2015-09-30 2025-03-28 Igm Biosciences Inc Módosított J-lánccal rendelkezõ kötõmolekulák
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
CN113388638A (zh) * 2021-04-13 2021-09-14 中国人民解放军西部战区总医院 一种同时结合TGFβ和VEGF的双靶点融合蛋白质粒的构建方法
WO2023250481A2 (en) * 2022-06-23 2023-12-28 Fuller Laboratories Rickettsia igm assay
EP4602367A2 (en) * 2022-10-12 2025-08-20 Massachusetts Institute Of Technology Library-scale methods for polypeptide functional analysis
CN116236584B (zh) * 2023-02-20 2024-03-22 四川大学 一种用于高效递送siRNA的多糖-多肽偶联物
WO2025140609A1 (zh) * 2023-12-28 2025-07-03 上海药明生物技术有限公司 一种构建生产去岩藻糖基化蛋白质的细胞的方法及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004514113A (ja) * 2000-06-02 2004-05-13 ユニバーシティー　オブ　コネティカット　ヘルス　センター 熱ショックタンパク質受容体としてのα（２）マクログロブリン受容体およびその使用
JP2006254919A (ja) * 1992-07-17 2006-09-28 Dana Farber Cancer Inst Inc 標的分子の細胞内結合方法
JP2009514528A (ja) * 2005-11-03 2009-04-09 フレッド ハッチンソン キャンサー リサーチ センター Ｎｋｇ２ｄ陽性ｃｄ４＋細胞による免疫応答の負の免疫調節法
US20120172253A1 (en) * 2009-05-04 2012-07-05 Roland Wolkowicz Compositions and methods for identifying enzyme and transport protein inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CN102459591B (zh) * 2009-05-20 2015-05-13 诺维莫尼公司 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006254919A (ja) * 1992-07-17 2006-09-28 Dana Farber Cancer Inst Inc 標的分子の細胞内結合方法
JP2004514113A (ja) * 2000-06-02 2004-05-13 ユニバーシティー　オブ　コネティカット　ヘルス　センター 熱ショックタンパク質受容体としてのα（２）マクログロブリン受容体およびその使用
JP2009514528A (ja) * 2005-11-03 2009-04-09 フレッド ハッチンソン キャンサー リサーチ センター Ｎｋｇ２ｄ陽性ｃｄ４＋細胞による免疫応答の負の免疫調節法
US20120172253A1 (en) * 2009-05-04 2012-07-05 Roland Wolkowicz Compositions and methods for identifying enzyme and transport protein inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TARJA T. LESKELA, PILIA M. H. MARKKANEN, E. MARITTA PIETILA, ET EL.: "Opioid Receptor Pharmacological Chaperones Act by Binding and Stabilized Newly Synthesized Receptor", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. Vol.282, No.32., JPN6017048146, 10 August 2007 (2007-08-10), US, pages 23171 - 23183, ISSN: 0003702771 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020510438A (ja) * 2017-03-15 2020-04-09 オックスフォード ジェネティクス リミテッドＯｘｆｏｒｄ Ｇｅｎｅｔｉｃｓ Ｌｉｍｉｔｅｄ 抗体の選択方法

Also Published As

Publication number Publication date
US9487773B2 (en) 2016-11-08
US20140249044A1 (en) 2014-09-04
WO2014133405A3 (en) 2015-02-26
ES2872048T3 (es) 2021-11-02
EP2962103A2 (en) 2016-01-06
EP3588089A1 (en) 2020-01-01
EP3588089B1 (en) 2021-03-10
PT3588089T (pt) 2021-06-02
WO2014133405A2 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
US9487773B2 (en) Cell-based methods for coupling protein interactions and binding molecule selection
US20240018224A1 (en) Anti-gpc3 antibody
JP5685274B2 (ja) 結合タンパク質の混合物
Ren et al. Function-based high-throughput screening for antibody antagonists and agonists against G protein-coupled receptors
US12221484B2 (en) Anti-NMDA receptor antibodies and methods of use
US20210116455A1 (en) Specificity assay for novel target antigen binding moieties
JP2024001060A (ja) 抗体の選択方法
Lomakin et al. Two-dimensional high-throughput on-cell screening of immunoglobulins against broad antigen repertoires
US20220154174A1 (en) Method of Selecting for Antibodies
CN116323922A (zh) 筛选靶向CD47-SIRPα免疫检查点的候选药物的方法和试剂盒
EP3661959A2 (en) Methods and compositions for ligand directed antibody design
Talucci et al. Molecular dissection of an immunodominant epitope in Kv1. 2-exclusive autoimmunity
US20190361013A1 (en) Intrabodies targeting post-translational modifications of native proteins and method for obtaining them
Štafl et al. Heterologous avian system for quantitative analysis of Syncytin-1 interaction with ASCT2 receptor
CN111201239A (zh) 用于开发特异于表位翻译后修饰状态的抗体的方法和组合物
IL269472B1 (en) Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
Protopapadakis et al. Isolation and characterization of human anti‐acetylcholine receptor monoclonal antibodies from transgenic mice expressing human immunoglobulin loci
US20250115898A1 (en) Systems and methods for simultaneous detection of antigens and ligands thereof
Omar Expression of Functional Anti-p24 scFv 183-H12-5C in HEK293T and Jurkat T Cells
US11878065B2 (en) Reporter protein fused antibodies
Shivange et al. An Innovative antibody-based Plug-and-Play strategy for SARS-CoV-2
松澤峻 Guinea pig immunoglobulin VH and VL repertoire analysis for a novel guinea pig monoclonal antibody platform
JP2024545273A (ja) 哺乳動物細胞における異種ポリペプチドの効率的な発現および分泌に関するシグナルペプチドのスクリーニング法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170301

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180730